Personalized Combination Therapy in Bladder Cancer: cAMP Modulators Synergize with 5-FU and Modulate Redox Programs
cAMP modulators selectively potentiate 5-FU in bladder cancer cells and modulate redox programs (notably with terbutaline), supporting a biomarker-guided combination strategy (e.g., β2-AR/PDE3/PI3K-Akt features) for personalized therapy in bladder cancer; mechanistic and in vivo validation are warranted.
Authors
- Eduarda Ribeiro (ORCID: https://orcid.org/0009-0009-5370-9586)
- Nuno Vale
Institutions
- Universidade do Porto (PT)
Publication Details
- Journal
- Cancers
- Published
- 2026-02-09
- DOI
- https://doi.org/10.3390/cancers18040562
- Primary Topic
- Phosphodiesterase function and regulation
- Type
- article
- Field-Weighted Citation Impact
- 0.00